A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Clinical trial NCT03900429 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03900429
- Sponsor
- Madrigal Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-28
- Primary completion
- 2028-01-01
- Enrollment
- 1759
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.